Cargando…

Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina

We evaluated results of temozolomide (TMZ) therapy in six patients, aged 34–78 years, presenting aggressive pituitary tumors. In all the patients tested O(6)-methylguanine-DNA methyltransferase (MGMT) immunoexpression in surgical specimens was absent. Patients received temozolomide 140–320 mg/day fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruno, Oscar D., Juárez-Allen, Lea, Christiansen, Silvia B., Manavela, Marcos, Danilowicz, Karina, Vigovich, Carlos, Gómez, Reynaldo M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461777/
https://www.ncbi.nlm.nih.gov/pubmed/26106414
http://dx.doi.org/10.1155/2015/587893
_version_ 1782375552911409152
author Bruno, Oscar D.
Juárez-Allen, Lea
Christiansen, Silvia B.
Manavela, Marcos
Danilowicz, Karina
Vigovich, Carlos
Gómez, Reynaldo M.
author_facet Bruno, Oscar D.
Juárez-Allen, Lea
Christiansen, Silvia B.
Manavela, Marcos
Danilowicz, Karina
Vigovich, Carlos
Gómez, Reynaldo M.
author_sort Bruno, Oscar D.
collection PubMed
description We evaluated results of temozolomide (TMZ) therapy in six patients, aged 34–78 years, presenting aggressive pituitary tumors. In all the patients tested O(6)-methylguanine-DNA methyltransferase (MGMT) immunoexpression in surgical specimens was absent. Patients received temozolomide 140–320 mg/day for 5 days monthly for at least 3 months. In two patients minimum time for evaluation could not be reached because of death in a 76-year-old man with a malignant prolactinoma and of severe neutro-thrombopenia in a 47-year-old woman with nonfunctioning pituitary adenoma. In two patients (a 34-year-old acromegalic woman and a 39-year-old woman with Nelson's syndrome) no response was observed after 4 and 6 months, respectively, and the treatment was stopped. Conversely, two 52- and 42-year-old women with Cushing's disease had long-term total clinical and radiological remissions which persisted after stopping temozolomide. We conclude that TMZ therapy may be of variable efficacy depending on—until now—incompletely understood factors. Cooperative work on a greater number of cases of aggressive pituitary tumors should be crucial to establish the indications, doses, and duration of temozolomide administration.
format Online
Article
Text
id pubmed-4461777
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-44617772015-06-23 Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina Bruno, Oscar D. Juárez-Allen, Lea Christiansen, Silvia B. Manavela, Marcos Danilowicz, Karina Vigovich, Carlos Gómez, Reynaldo M. Int J Endocrinol Clinical Study We evaluated results of temozolomide (TMZ) therapy in six patients, aged 34–78 years, presenting aggressive pituitary tumors. In all the patients tested O(6)-methylguanine-DNA methyltransferase (MGMT) immunoexpression in surgical specimens was absent. Patients received temozolomide 140–320 mg/day for 5 days monthly for at least 3 months. In two patients minimum time for evaluation could not be reached because of death in a 76-year-old man with a malignant prolactinoma and of severe neutro-thrombopenia in a 47-year-old woman with nonfunctioning pituitary adenoma. In two patients (a 34-year-old acromegalic woman and a 39-year-old woman with Nelson's syndrome) no response was observed after 4 and 6 months, respectively, and the treatment was stopped. Conversely, two 52- and 42-year-old women with Cushing's disease had long-term total clinical and radiological remissions which persisted after stopping temozolomide. We conclude that TMZ therapy may be of variable efficacy depending on—until now—incompletely understood factors. Cooperative work on a greater number of cases of aggressive pituitary tumors should be crucial to establish the indications, doses, and duration of temozolomide administration. Hindawi Publishing Corporation 2015 2015-05-27 /pmc/articles/PMC4461777/ /pubmed/26106414 http://dx.doi.org/10.1155/2015/587893 Text en Copyright © 2015 Oscar D. Bruno et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Bruno, Oscar D.
Juárez-Allen, Lea
Christiansen, Silvia B.
Manavela, Marcos
Danilowicz, Karina
Vigovich, Carlos
Gómez, Reynaldo M.
Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina
title Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina
title_full Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina
title_fullStr Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina
title_full_unstemmed Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina
title_short Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina
title_sort temozolomide therapy for aggressive pituitary tumors: results in a small series of patients from argentina
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461777/
https://www.ncbi.nlm.nih.gov/pubmed/26106414
http://dx.doi.org/10.1155/2015/587893
work_keys_str_mv AT brunooscard temozolomidetherapyforaggressivepituitarytumorsresultsinasmallseriesofpatientsfromargentina
AT juarezallenlea temozolomidetherapyforaggressivepituitarytumorsresultsinasmallseriesofpatientsfromargentina
AT christiansensilviab temozolomidetherapyforaggressivepituitarytumorsresultsinasmallseriesofpatientsfromargentina
AT manavelamarcos temozolomidetherapyforaggressivepituitarytumorsresultsinasmallseriesofpatientsfromargentina
AT danilowiczkarina temozolomidetherapyforaggressivepituitarytumorsresultsinasmallseriesofpatientsfromargentina
AT vigovichcarlos temozolomidetherapyforaggressivepituitarytumorsresultsinasmallseriesofpatientsfromargentina
AT gomezreynaldom temozolomidetherapyforaggressivepituitarytumorsresultsinasmallseriesofpatientsfromargentina